[go: up one dir, main page]

UY27704A1 - Compuestos que modulan la actividad de ppar - Google Patents

Compuestos que modulan la actividad de ppar

Info

Publication number
UY27704A1
UY27704A1 UY27704A UY27704A UY27704A1 UY 27704 A1 UY27704 A1 UY 27704A1 UY 27704 A UY27704 A UY 27704A UY 27704 A UY27704 A UY 27704A UY 27704 A1 UY27704 A1 UY 27704A1
Authority
UY
Uruguay
Prior art keywords
compounds
ppar
activity
modulate
describes
Prior art date
Application number
UY27704A
Other languages
English (en)
Inventor
Xue-Min Cheng
Gary F Filzen
Andrew G Geyer
Bharat K Trivedi
Gary Ouano Erasga
Chistase Lee
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of UY27704A1 publication Critical patent/UY27704A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta invención describe compuestos que alteran la actividad de PPAR. La invención tambien describe sales farmacéuticamente aceptables de los compuestos, composiciones farmacéuticamente aceptables que comprenden los compuestos o sus sales, y métodos para utilizarlas como agentes terapéuticos para tratar o prevenir hiperlipidemia e hipercolesteremia en un mamífero. La presente invención también describe un método para obtener los compuestos descriptos.
UY27704A 2002-03-07 2003-03-07 Compuestos que modulan la actividad de ppar UY27704A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36240002P 2002-03-07 2002-03-07

Publications (1)

Publication Number Publication Date
UY27704A1 true UY27704A1 (es) 2003-10-31

Family

ID=27789156

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27704A UY27704A1 (es) 2002-03-07 2003-03-07 Compuestos que modulan la actividad de ppar

Country Status (29)

Country Link
US (1) US6833380B2 (es)
EP (1) EP1485091A1 (es)
JP (1) JP2005524665A (es)
KR (1) KR20040091694A (es)
CN (1) CN1638768A (es)
AP (1) AP2004003123A0 (es)
AR (1) AR038883A1 (es)
AU (1) AU2003207891A1 (es)
BR (1) BR0308221A (es)
CA (1) CA2476580A1 (es)
CO (1) CO5601013A2 (es)
EA (1) EA200401160A1 (es)
EC (1) ECSP045275A (es)
GT (1) GT200300053A (es)
HR (1) HRP20040810A2 (es)
IL (1) IL163768A0 (es)
IS (1) IS7399A (es)
MA (1) MA27182A1 (es)
MX (1) MXPA04008624A (es)
NO (1) NO20044245L (es)
OA (1) OA12781A (es)
PA (1) PA8568701A1 (es)
PE (1) PE20031010A1 (es)
PL (1) PL372971A1 (es)
TN (1) TNSN04167A1 (es)
TW (1) TW200400027A (es)
UY (1) UY27704A1 (es)
WO (1) WO2003074052A1 (es)
ZA (1) ZA200406491B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867224B2 (en) * 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
US20050203151A1 (en) * 2003-12-19 2005-09-15 Kalypsys, Inc. Novel compounds, compositions and uses thereof for treatment of metabolic disorders and related conditions
WO2005105736A1 (en) 2004-05-05 2005-11-10 Novo Nordisk A/S Novel compounds, their preparation and use
EP1745003B1 (en) 2004-05-05 2010-10-27 High Point Pharmaceuticals, LLC Novel compounds, their preparation and use
EP1751120A4 (en) * 2004-05-25 2010-05-05 Metabolex Inc SUBSTITUTED TRIAZOLE AS PPAR MODULATORS AND MANUFACTURING METHOD THEREFOR
WO2005115384A2 (en) * 2004-05-25 2005-12-08 Metabolex, Inc. Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation
ATE529404T1 (de) 2005-06-30 2011-11-15 High Point Pharmaceuticals Llc Phenoxyessigsäuren als ppar-delta-aktivatoren
CN1896069B (zh) * 2005-07-15 2011-10-05 中国科学院上海药物研究所 一类取代噻唑-4酮化合物、制备方法和用途
CN103224477A (zh) 2005-12-22 2013-07-31 高点制药有限责任公司 作为PPAR-δ活化剂的苯氧基乙酸
EP1999098A2 (en) 2006-03-09 2008-12-10 High Point Pharmaceuticals, LLC Compounds that modulate ppar activity, their preparation and use
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
KR20100065191A (ko) 2007-09-14 2010-06-15 오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 １,３-이치환된 ４-(아릴-ｘ-페닐)-１ｈ-피리딘-２-온
DE602008004794D1 (de) 2007-09-14 2011-03-10 Addex Pharmaceuticals Sa 1',3'-disubstituierte 4-phenyl-3,4,5,6-tetrahydro-2h,1'h-ä1,4'übipyridinyl-2'-one
AU2008297877C1 (en) 2007-09-14 2013-11-07 Addex Pharma S.A. 1,3-disubstituted-4-phenyl-1 H-pyridin-2-ones
US8785486B2 (en) 2007-11-14 2014-07-22 Janssen Pharmaceuticals, Inc. Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
EP2344470B1 (en) 2008-09-02 2013-11-06 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
CN102186477B (zh) 2008-10-16 2013-07-17 奥梅-杨森制药有限公司 作为代谢型谷氨酸受体调节剂的吲哚和苯并吗啉衍生物
CN102232074B (zh) 2008-11-28 2014-12-03 奥梅-杨森制药有限公司 作为代谢性谷氨酸盐受体调节剂的吲哚和苯并噁嗪衍生物
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
WO2010130422A1 (en) 2009-05-12 2010-11-18 Ortho-Mcneil-Janssen Pharmaceuticals, Inc 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
AR076861A1 (es) 2009-05-12 2011-07-13 Addex Pharma Sa Derivados de 1,2,4-triazolo (4,3-a)piridina y su uso como moduladores alostericos positivos de los receptores de mglur2
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
CA2814998C (en) 2010-11-08 2019-10-29 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
ES2552455T3 (es) 2010-11-08 2015-11-30 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
ES2811087T3 (es) 2013-09-09 2021-03-10 Vtv Therapeutics Llc Uso de agonistas de PPAR-delta para tratar la atrofia muscular
PH12019500127B1 (en) 2014-01-21 2022-05-04 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
SMT201900545T1 (it) 2014-01-21 2019-11-13 Janssen Pharmaceutica Nv Combinazioni comprendenti modulatori allosterici positivi o agonisti ortosterici del recettore glutammatergico metabotropico sottotipo 2 e loro utilizzo
CN113045523B (zh) * 2019-12-27 2022-09-23 上海泓博智源医药股份有限公司 一种咪唑啉吡啶化合物中间体的制备方法
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997028149A1 (en) 1996-02-02 1997-08-07 Merck & Co., Inc. Method for raising hdl cholesterol levels
ATE236137T1 (de) 1996-02-02 2003-04-15 Merck & Co Inc Heterocyclische verbindungen als antidiabetische mittel und für die behandlung von fettleibigkeit
AU740444B2 (en) 1996-08-19 2001-11-01 Japan Tobacco Inc. Propionic acid derivatives and use thereof
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
DK1206457T3 (da) 1999-08-27 2004-02-16 Lilly Co Eli Biaryl-oxa(thia)zolderivater og deres anvendelse som modulatorer PPAP'ER
AU2001284658A1 (en) 2000-08-23 2002-03-13 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
DK1313716T3 (da) 2000-08-23 2007-08-27 Lilly Co Eli Oxazolyl-arylpropionsyrederivater og anvendelse deraf som PPAR-agonister
GB0031109D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
US7091225B2 (en) 2000-12-20 2006-08-15 Smithkline Beecham Corporation Substituted oxazoles and thiazoles as hPPAR alpha agonists
GB0031107D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
GB0111523D0 (en) 2001-05-11 2001-07-04 Glaxo Group Ltd Chemical compounds
MXPA03010867A (es) 2001-05-29 2004-02-27 Kyoto Pharma Ind Nuevos derivados heterociclicos y uso farmaceutico de los mismos.
CN1578659A (zh) 2001-06-07 2005-02-09 伊莱利利公司 过氧化物酶体增殖剂激活的受体(ppar)的调节剂
DE60226441D1 (de) 2001-06-18 2008-06-19 Ono Pharmaceutical Co Tetrahydrochinolinderivatverbindung und die verbindung als wirkstoff enthaltendes arzneimittel
AR036237A1 (es) 2001-07-27 2004-08-25 Bayer Corp Derivados del acido indan acetico, intermediarios, y metodo para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento
WO2003024395A2 (en) 2001-09-14 2003-03-27 Tularik Inc. Linked biaryl compounds
US6867224B2 (en) 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
US20030207924A1 (en) 2002-03-07 2003-11-06 Xue-Min Cheng Compounds that modulate PPAR activity and methods of preparation
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation

Also Published As

Publication number Publication date
CN1638768A (zh) 2005-07-13
GT200300053A (es) 2003-10-10
ZA200406491B (en) 2006-05-31
NO20044245L (no) 2004-10-06
TNSN04167A1 (fr) 2007-03-12
AP2004003123A0 (en) 2004-09-30
ECSP045275A (es) 2004-10-26
EA200401160A1 (ru) 2005-02-24
OA12781A (en) 2006-07-07
CA2476580A1 (en) 2003-09-12
HRP20040810A2 (en) 2004-12-31
MA27182A1 (fr) 2005-01-03
WO2003074052A1 (en) 2003-09-12
EP1485091A1 (en) 2004-12-15
BR0308221A (pt) 2005-01-04
PE20031010A1 (es) 2003-12-12
US20030207916A1 (en) 2003-11-06
AR038883A1 (es) 2005-02-02
MXPA04008624A (es) 2004-12-06
CO5601013A2 (es) 2006-01-31
PA8568701A1 (es) 2003-11-12
IS7399A (is) 2004-08-12
AU2003207891A1 (en) 2003-09-16
TW200400027A (en) 2004-01-01
PL372971A1 (en) 2005-08-08
JP2005524665A (ja) 2005-08-18
KR20040091694A (ko) 2004-10-28
US6833380B2 (en) 2004-12-21
IL163768A0 (en) 2005-12-18

Similar Documents

Publication Publication Date Title
UY27704A1 (es) Compuestos que modulan la actividad de ppar
UY27696A1 (es) Compuestos que modulan la actividad de ppar
UY27695A1 (es) Compuestos que modulan la actividad de ppar.
DOP2003000620A (es) Compuestos que modulan la actividad de ppar y procedimientos para su preparación
DOP2004000881A (es) Compuestos que modulan la actividad de ppar y procedimientos de preparacion
UY39188A (es) Imidazopiridazinas como moduladores de il-17
ECSP045098A (es) Procedimientos para tratar enfermedades neovasculares oculares
ECSP077270A (es) Ácidos de tiazolo - naftilo
MX382184B (es) Cisteamina recubierta entericamente, cistamina y derivados de ellas.
ECSP077280A (es) Moduladores de quinasa de pirrolo-piridina
GT200900283A (es) "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
CR8497A (es) Derivados de azepinoindol como agentes farmaceuticos
AR062875A1 (es) Compuestos de n- metilaminometil isoindol y composiciones que los comprenden y metodos para utilizarlos
ECSP088352A (es) Derivados de indol 1,3-disustituido para su uso como moduladores de ppar
CR10314A (es) Compuestos que tienen actividad en el receptor m 1 y sus usos en medicina
CR10600A (es) Ciclopenta (d) pirimidinas hidroxiladas y metoxiladas como inhibidores de akt proteina quinasa
BRMU8400812Y1 (pt) aperfeiçoamento introduzido em fonte de luz para tratamento da hiperbilirrubinemia por fototerapia.
SV2002000022A (es) Inhibidores de recanalizacion de la monoamida para el tratamiento de los desordenes del sistema nervioso central ref. pc10434
CR9903A (es) Compuestos antihipercolesterolemicos
AR029837A1 (es) Anilidas de acidos sulfonicos substituidas
CL2019000768A1 (es) Compuestos de aza-indazol para usar en lesiones de tendones y/o ligamentos.
BRPI0514549A (pt) ácidos de pirrol-naftila como inibidores de pai-1
CL2023002486A1 (es) Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso
ECSP067008A (es) Compuestos de opioide carboxamido
UY26265A1 (es) Compuestos calciolíticos

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150126